Article citationsMore>>

Capone, C.A., Subramony, A., Sweberg, T., Schneider, J., Shah, S., Rubin, L., Schleien, C., the Northwell Health COVID-19 Research Consortium, Epstein, S., Johnson, J.C., Kessel, A., Misra, N., Mitchell, E., Palumbo, N., Rajan, S., Rocker, J., Williamson, K. and Davidson, K.W. (2020) Characteristics, Cardiac Involvement, and Outcomes of Multisystem Inflammatory Syndrome of Childhood Associated with Severe Acute Respiratory Syndrome Coronavirus 2 Infection. The Journal of Pediatrics, 224, 141-145.
https://doi.org/10.1016/j.jpeds.2020.06.044

has been cited by the following article:

• TITLE: Multi-Systemic Inflammatory Syndrome in Children

  AUTHORS: Ilham Tadmori, Soukaina Seddiki, Samir Atmani, Moustapha Hida

  KEYWORDS: Multisystemic Inflammatory Syndrome, Child, COVID-19, PIMS

  JOURNAL NAME: Open Journal of Pediatrics, Vol.13 No.4, July 21, 2023

  ABSTRACT: The objective of our work is to study the multi-systemic inflammatory syndrome (PIMS) in children, to determine its frequency, by analyzing the epidemiological, clinical, paraclinical, therapeutic, and evolutionary profile of these patients. A retrospective study spanning a period of 2 years from April 2020 to March 2022. It concerns all children under the age of 16 admitted and cared for in the pediatric emergency department of the university hospital Hassan II of Fez for multi-system inflammatory syndrome (PIMS). Twenty cases of PIMS were collected over this period. Multi-system inflammatory syndrome in children has been described in temporal association with COVID-19, usually within 2 to 6 weeks of illness or exposure. The age of the patients varies between 8 months and 15 years. All patients presented with fever and cutaneous signs, followed by digestive signs and neurological signs. The inflammatory syndrome is frankly positive in all patients who had a COVID-19 PCR and/or positive serology. The treatment is based on the administration of immunoglobulins in association with corticosteroid therapy and non-specific antibiotic therapy in the majority of cases (80%). The evolution was favorable. PIMS should be considered in all children presenting with a clinical and/or biological inflammatory syndrome associated with COVID-19.